BioCentury
ARTICLE | Company News

Auspherix infectious news

December 9, 2013 8:00 AM UTC

Auspherix debuted with A$1 million ($914,700) in seed funding from Australia's Medical Research Commercialization Fund (MRCF) to develop antibiotics to treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the University of Technology Sydney that covers antibiotics with undisclosed mechanisms of action which were identified at the institute. The seed funding will be used for lead optimization and preclinical development. ...